Per Thor Straten

This inventor holds 8 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 4 EPO patents. Top assignees: Io Biotech Aps, Io Bioech Aps, Kraeftens Bekaempelse. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Per Thor Straten. Retrieved from https://idiyas.com/inventor/per-thor-straten

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 3

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 2.0

ph-index = 3

Forward Citations = 21(Granted Patents)

Company Filing History:

Kraeftens Bekaempelse

Years Active: 2010-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12233103 - Indoleamine 2,3-dioxygenase based immunotherapy (2025-02-25),

2. 11648302 - Indoleamine 2,3-dioxygenase based immunotherapy (2023-05-16),

3. 11324813 - Indoleamine 2,3-dioxygenase based immunotherapy (2022-05-10),

4. 10258678 - Indoleamine 2,3-dioxygenase based immunotherapy (2019-04-16),

5. 9433666 - Indoleamine 2,3-dioxygenase based immunotherapy (2016-09-06),

6. 9163077 - RhoC-based immunotherapy (2015-10-20),

7. 7842294 - Proteins belonging to the Bcl-2 family and fragments thereof, and their use in cancer patients (2010-11-30),

8. 7687465 - Therapeutic cancer vaccine (2010-03-30),

Title: Per Thor Straten: Innovator in Cancer Immunotherapy

Introduction

Per Thor Straten is a notable inventor based in Hvidovre, Denmark. He has made significant contributions to the field of cancer immunotherapy, holding a total of 8 patents. His work focuses on innovative approaches to enhance anti-cancer immune responses, particularly through the use of Indoleamine 2,3-dioxygenase (IDO).

Latest Patents

Straten's latest patents revolve around Indoleamine 2,3-dioxygenase based immunotherapy. This invention pertains to the prophylaxis and therapy of cancer. It provides a method utilizing IDO or peptide fragments capable of eliciting anti-cancer immune responses. The invention also discusses the use of IDO specific T-cells for cancer treatment, potentially in combination with other immunotherapies. Furthermore, it addresses the use of these medicaments alongside cancer chemotherapy treatments. The invention extends to the prophylaxis and therapy of infections, utilizing similar mechanisms for treatment, diagnosis, and prognosis.

Career Highlights

Throughout his career, Per Thor Straten has worked with several companies, including Io Biotech Aps and Survac Aps. His expertise in immunotherapy has positioned him as a key figure in the development of innovative cancer treatments.

Collaborations

Straten has collaborated with notable professionals in his field, including Mads Hald Andersen. These partnerships have contributed to the advancement of his research and the successful implementation of his inventions.

Conclusion

Per Thor Straten's work in cancer immunotherapy exemplifies the impact of innovative thinking in medical science. His patents and collaborations continue to pave the way for new treatment options in the fight against cancer.

Profile summary based on public USPTO records.